Trial
NCT05405309
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Utah
Collaborators
Repare Therapeutics
Condition
Chronic Lymphocytic Leukemia
Intervention
RP-3500
Why stopped
This study was terminated due to sponsor de-activation of all programs associated with RP-3500 (camonsertib).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-03